Mangoceuticals announces the development of proprietary formulations of Enclomiphene Citrate, Pregnenolone and Dehydroepiandrosterone in an Oral Dissolvable Tablet aimed at restoring hormonal balance and naturally increasing testosterone levels in men. The new compounded product will be named “MOJO” and sold exclusively on MangoRx’s website on a subscription basis at a price of $199 per month. MOJO represents the groundbreaking advancement in addressing male hormonal imbalances, particularly hypogonadism through this unique and powerful formulation and will be offered as an alternative to the Company’s existing FDA approved oral Testosterone Replacement Therapy, PRIME by MangoRx, powered by Kyzatrex.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGRX:
- Mangoceuticals completes first batch of mango ED products for LATAM
- Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets
- MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts
- Mangoceuticals engages Crakmedia for digital marketing efforts
- MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications